Richard N. Kender's most recent trade in Longeveron Inc - Ordinary Shares - Class A was a trade of 17,000 Class A Common Stock done . Disclosure was reported to the exchange on July 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Longeveron Inc (Class A) | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 17,000 | 33,000 | - | 0 | Class A Common Stock | |
| Seres Therapeutics Inc | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 6,250 | 23,000 | - | 0 | Ordinary Shares | |
| Omega Therapeutics Inc | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Longeveron Inc (Class A) | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 10 May 2024 | 16,000 | 16,000 | - | 1.5 | 23,280 | Class A Common Stock |
| Seres Therapeutics Inc | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2024 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Richard N. Kender | Director | 02 Jan 2024 | 12,000 | 12,000 | - | - | Stock Option (right to buy) | ||
| Bicycle Therapeutics PLC (ADR) | Richard N. Kender | Director | 02 Jan 2024 | 6,000 | 16,750 | - | 0 | Ordinary Shares | ||
| Seres Therapeutics Inc | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 3.15 per share. | 05 Jul 2022 | 63,492 | 63,492 (0%) | 0% | 3.2 | 200,000 | COMMON STOCK |
| Seres Therapeutics Inc | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Seres Therapeutics Inc | Richard N. Kender | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 35,000 | 35,000 | - | - | Stock Option (right to buy) |